公开(公告)号：US20220220077A1

公开(公告)日：2022-07-14

申请号：US17606303

申请日：2020-05-19

申请人： H. Lundbeck A/S

发明人： Morten Jørgensen ,  Erhad Ascic ,  Martin Juhl ,  Klaus Gjervig Jensen ,  Ask Püschl ,  Benny Bang-Andersen

IPC分类号： C07D221/08 ,  C07F9/576

摘要： The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

公开(公告)号：US11279682B2

公开(公告)日：2022-03-22

申请号：US16294647

申请日：2019-03-06

申请人： H. Lundbeck A/S

发明人： Heidi Lopez de Diego ,  Kim Lasse Christensen ,  Rene Holm ,  Jens Kateb

IPC分类号： C07D295/096 ,  C07D207/28

摘要： The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.

公开(公告)号：US11111289B2

公开(公告)日：2021-09-07

申请号：US16248284

申请日：2019-01-15

申请人： H. LUNDBECK A/S

发明人： Brian Robert Kovacevich ,  Leon F. Garcia-Martinez ,  Katie Olson Anderson ,  Benjamin H. Dutzar ,  Jens J. Billgren ,  John A. Latham ,  Danielle M. Mitchell ,  Patricia Dianne McNeill ,  Nicole M. Janson ,  Maria-Cristina Loomis

IPC分类号： C07K16/18 ,  A61P25/00 ,  C07K16/26 ,  A61K31/485 ,  A61K39/395 ,  A61K49/00 ,  A61K39/00

摘要： The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

公开(公告)号：US20210236634A1

公开(公告)日：2021-08-05

申请号：US17109028

申请日：2020-12-01

申请人： H. Lundbeck A/S

发明人： Pekka Kallunki ,  Paul E.G. Kristjansen

IPC分类号： A61K39/395 ,  A61K31/197 ,  A61P25/28 ,  A61P25/16

摘要： The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.

公开(公告)号：US11059798B2

公开(公告)日：2021-07-13

申请号：US16672870

申请日：2019-11-04

申请人： H. Lundbeck A/S

发明人： Morten Jorgensen ,  Peter Hongaard Andersen ,  Klaus Gjervig Jensen

IPC分类号： C07D295/073 ,  C07B59/00 ,  C07D241/04 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/554 ,  C07C45/61 ,  C07C45/67

摘要： The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.

公开(公告)号：US20210054057A1

公开(公告)日：2021-02-25

申请号：US16895471

申请日：2020-06-08

申请人： H. Lundbeck A/S

发明人： Pekka KALLUNKI ,  Karina FOG ,  Louise Buur VESTERAGER ,  Ann-Louise BERGSTRÔM ,  Florence SOTTY ,  David SATIJN ,  Edward VAN DEN BRINK ,  Paul PARREN ,  Rik RADEMAKER ,  Tom VINK ,  Ibrahim John MALIK ,  Liliana Christina Pereira MONTEZINHO

IPC分类号： C07K16/18 ,  A61K51/00 ,  A61K39/395 ,  A61P25/16 ,  A61P25/28 ,  G01N33/68

摘要： The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

公开(公告)号：US20210047342A1

公开(公告)日：2021-02-18

申请号：US16916681

申请日：2020-06-30

申请人： H. Lundbeck A/S

发明人： John Paul Kilburn ,  Erhad Ascic ,  Mauro Marigo ,  Laurent David

IPC分类号： C07D495/04

摘要： The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

公开(公告)号：US20210015794A1

公开(公告)日：2021-01-21

申请号：US17060796

申请日：2020-10-01

申请人： H. Lundbeck A/S

发明人： Jan Kehler ,  Karsten Juhl ,  Mauro Marigo ,  Paulo Jorge Vieira Vital ,  Mikkel Jessing ,  Morten Langgård ,  Lars Kyhn Rasmussen ,  Carl Martin Sebastian Clementson

IPC分类号： A61K31/4162 ,  C07D471/04 ,  A61K31/4745 ,  C07D413/04

摘要： The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

公开(公告)号：US20210009571A1

公开(公告)日：2021-01-14

申请号：US16955926

申请日：2018-12-19

申请人： H. Lundbeck A/S

发明人： Jan Kehler ,  Lars Kyhn Rasmussen ,  Morten Langgârd ,  Mikkel Jessing ,  Paulo Jorge Vieira Vital ,  Karsten Juhl ,  Mauro Marigo

IPC分类号： C07D405/14 ,  C07D401/14

摘要： The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

公开(公告)号：US10800836B2

公开(公告)日：2020-10-13

申请号：US15207859

申请日：2016-07-12

申请人： H. Lundbeck A/S

发明人： Pekka Kallunki ,  Karina Fog ,  Louise Buur Vesterager ,  Ann-Louise Bergstrôm ,  Florence Sotty ,  David Satijn ,  Edward van den Brink ,  Paul Parren ,  Rik Rademaker ,  Tom Vink ,  Ibrahim John Malik ,  Liliana Christina Pereira Montezinho

IPC分类号： C07K16/18 ,  A61K39/395 ,  A61K51/00 ,  A61P25/16 ,  A61P25/28 ,  G01N33/68 ,  A61K39/00

摘要： The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.